Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

616
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
616
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

305
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
305

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of anticoagulation in patients with heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary bypass: guidance from the ISTH SSC on Perioperative and Critical Care Haemostasis and Thrombosis.

Journal of thrombosis and haemostasis : JTH·2026
Same author

How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Evaluation of anticoagulation management in patients with suspected heparin-induced thrombocytopenia awaiting diagnosis confirmation.

Journal of thrombosis and thrombolysis·2026
Same author

Thrombin generation and the pharmacodynamics of parenteral anticoagulants.

Pharmacological reviews·2026
Same author

Global survey of women's awareness of pregnancy- and postpartum-associated venous thromboembolism (World Thrombosis Day 2025).

Research and practice in thrombosis and haemostasis·2026
Same author

Redefining Fibrinolytic Insufficiency in Sepsis-Associated DIC.

Seminars in thrombosis and hemostasis·2026

Related Experiment Video

Updated: Jun 5, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.7K

Troubleshooting heparin resistance.

Cheryl L Maier1, Jean M Connors2, Jerrold H Levy3

  • 1Department of Pathology and Laboratory Medicine, Emory School of Medicine, Atlanta, GA.

Hematology. American Society of Hematology. Education Program
|December 7, 2024
PubMed
Summary
This summary is machine-generated.

Heparin resistance occurs when unfractionated heparin (UFH) fails to achieve therapeutic anticoagulation. Causes include hypercoagulability and incorrect dosing, necessitating alternative treatments or monitoring methods.

More Related Videos

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

468
Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
10:41

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity

Published on: February 17, 2017

8.0K

Related Experiment Videos

Last Updated: Jun 5, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.7K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

468
Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
10:41

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity

Published on: February 17, 2017

8.0K

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Background:

  • Heparin resistance is defined as the failure of unfractionated heparin (UFH) to achieve therapeutic anticoagulation levels despite appropriate dosing.
  • Current monitoring assays like activated partial thromboplastin time (aPTT) and activated clotting time (ACT) are susceptible to interference from factors like inflammation and infection, particularly during events such as the COVID-19 pandemic.
  • This has led many institutions to adopt anti-Xa testing for more reliable heparin monitoring.

Purpose of the Study:

  • To clarify the definition and causes of heparin resistance.
  • To discuss the limitations of traditional heparin monitoring assays.
  • To outline current and alternative treatment strategies for heparin resistance.

Main Methods:

  • Review of existing literature on heparin resistance, anticoagulation monitoring, and treatment protocols.
  • Analysis of factors influencing heparin efficacy and monitoring assay reliability.
  • Synthesis of information regarding causes, diagnosis, and management of heparin resistance.

Main Results:

  • No established consensus exists for the "appropriate dose" or "predetermined level" of anticoagulation for defining heparin resistance.
  • Traditional clot-based assays (aPTT, ACT) are unreliable in certain clinical conditions, prompting a shift towards anti-Xa assays.
  • Identified causes of heparin resistance include hypercoagulability, antithrombin deficiency, thrombocytosis, antiphospholipid antibody syndromes, and the use ofandexanet alfa.
  • Treatment options involve adjusted UFH dosing, antithrombin supplementation, or alternative anticoagulants like direct thrombin inhibitors.

Conclusions:

  • Heparin resistance presents a significant clinical challenge due to undefined parameters and unreliable monitoring methods.
  • Understanding the multifactorial causes of heparin resistance is crucial for effective patient management.
  • Alternative anticoagulants and advanced monitoring techniques offer viable solutions for patients exhibiting heparin resistance.